Bank of New York Mellon Corp Reduces Stock Holdings in Artivion, Inc. (NYSE:AORT)

Bank of New York Mellon Corp lowered its position in Artivion, Inc. (NYSE:AORT) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 258,384 shares of the company’s stock after selling 1,697 shares during the quarter. Bank of New York Mellon Corp’s holdings in Artivion were worth $7,387,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quarry LP increased its position in Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares in the last quarter. R Squared Ltd purchased a new stake in Artivion during the 4th quarter worth about $39,000. Arcadia Investment Management Corp MI purchased a new stake in Artivion during the 4th quarter worth about $43,000. Venturi Wealth Management LLC purchased a new stake in Artivion during the 4th quarter worth about $78,000. Finally, GAMMA Investing LLC increased its position in Artivion by 21.8% during the 4th quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock worth $79,000 after purchasing an additional 497 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

AORT has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Finally, Stifel Nicolaus lowered their price target on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Stock Up 3.1 %

AORT opened at $24.15 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1,207.25 and a beta of 1.79. The business has a 50-day moving average of $28.66 and a two-hundred day moving average of $27.73. Artivion, Inc. has a 12 month low of $19.36 and a 12 month high of $32.33.

Artivion (NYSE:AORT) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, research analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Activity

In related news, CFO Lance A. Berry sold 3,259 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $89,003.29. Following the transaction, the chief financial officer now directly owns 75,805 shares of the company’s stock, valued at approximately $2,070,234.55. The trade was a 4.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 5,335 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $145,698.85. Following the transaction, the senior vice president now directly owns 149,799 shares in the company, valued at $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock valued at $2,356,223 in the last three months. Corporate insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.